Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Nolan R Vale"'
Autor:
Yong Li, Steven A Rosenberg, Paul F Robbins, Zhiya Yu, Maria Parkhurst, Billel Gasmi, Nikolaos Zacharakis, Todd D Prickett, Jared J Gartner, Sri Krishna, Stephanie L Goff, Satyajit Ray, Frank J Lowery, Sivasish Sindiri, Alakesh Bera, Noam Levin, Sanghyun P Kim, Charles A Marquardt, Nolan R Vale, Lior Levy, Tiffany Benzine, Robert V Masi, Rafiqul Islam
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 5 (2024)
Background Tumor-infiltrating lymphocytes (TILs) targeting neoantigens can effectively treat a selected set of metastatic solid cancers. However, harnessing TILs for cancer treatments remains challenging because neoantigen-reactive T cells are often
Externí odkaz:
https://doaj.org/article/f685ba7746d3429ab6dd6d6e8a83fc10
Autor:
Sanghyun P. Kim, Nolan R. Vale, Nikolaos Zacharakis, Sri Krishna, Zhiya Yu, Billel Gasmi, Jared J. Gartner, Sivasish Sindiri, Parisa Malekzadeh, Drew C. Deniger, Frank J. Lowery, Maria R. Parkhurst, Lien T. Ngo, Satyajit Ray, Yong F. Li, Victoria Hill, Maria Florentin, Robert V. Masi, Biman C. Paria, Noam Levin, Alakesh Bera, Elizabeth A. Hedges, Agnes Choi, Praveen D. Chatani, Anup Y. Parikh, Shoshana Levi, Samantha Seitter, Yong-Chen Lu, Zhili Zheng, Todd D. Prickett, Li Jia, Jonathan M. Hernandez, Chuong D. Hoang, Paul F. Robbins, Stephanie L. Goff, Richard M. Sherry, James C. Yang, Steven A. Rosenberg
Publikováno v:
Cancer Immunology Research. 10:932-946
Adoptive cellular therapy (ACT) targeting neoantigens can achieve durable clinical responses in patients with cancer. Most neoantigens arise from patient-specific mutations, requiring highly individualized treatments. To broaden the applicability of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cd7c2cf7704a11e5d74fd00ce2ec8d0
https://doi.org/10.1158/2326-6066.cir-22-0040
https://doi.org/10.1158/2326-6066.cir-22-0040
Autor:
Steven A. Rosenberg, James C. Yang, Richard M. Sherry, Stephanie L. Goff, Paul F. Robbins, Chuong D. Hoang, Jonathan M. Hernandez, Li Jia, Todd D. Prickett, Zhili Zheng, Yong-Chen Lu, Samantha Seitter, Shoshana Levi, Anup Y. Parikh, Praveen D. Chatani, Agnes Choi, Elizabeth A. Hedges, Alakesh Bera, Noam Levin, Biman C. Paria, Robert V. Masi, Maria Florentin, Victoria Hill, Yong F. Li, Satyajit Ray, Lien T. Ngo, Maria R. Parkhurst, Frank J. Lowery, Drew C. Deniger, Parisa Malekzadeh, Sivasish Sindiri, Jared J. Gartner, Billel Gasmi, Zhiya Yu, Sri Krishna, Nikolaos Zacharakis, Nolan R. Vale, Sanghyun P. Kim
Supplementary Figure from Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30e3f8c006b4d5783eb104fc14a96821
https://doi.org/10.1158/2326-6066.22545620.v1
https://doi.org/10.1158/2326-6066.22545620.v1
Autor:
Steven A. Rosenberg, James C. Yang, Richard M. Sherry, Stephanie L. Goff, Paul F. Robbins, Chuong D. Hoang, Jonathan M. Hernandez, Li Jia, Todd D. Prickett, Zhili Zheng, Yong-Chen Lu, Samantha Seitter, Shoshana Levi, Anup Y. Parikh, Praveen D. Chatani, Agnes Choi, Elizabeth A. Hedges, Alakesh Bera, Noam Levin, Biman C. Paria, Robert V. Masi, Maria Florentin, Victoria Hill, Yong F. Li, Satyajit Ray, Lien T. Ngo, Maria R. Parkhurst, Frank J. Lowery, Drew C. Deniger, Parisa Malekzadeh, Sivasish Sindiri, Jared J. Gartner, Billel Gasmi, Zhiya Yu, Sri Krishna, Nikolaos Zacharakis, Nolan R. Vale, Sanghyun P. Kim
Adoptive cellular therapy (ACT) targeting neoantigens can achieve durable clinical responses in patients with cancer. Most neoantigens arise from patient-specific mutations, requiring highly individualized treatments. To broaden the applicability of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83c6a0f591f57b24fb7e630d112f7f94
https://doi.org/10.1158/2326-6066.c.6550985.v1
https://doi.org/10.1158/2326-6066.c.6550985.v1
Autor:
Frank J. Lowery, Sri Krishna, Rami Yossef, Neilesh B. Parikh, Praveen D. Chatani, Nikolaos Zacharakis, Maria R. Parkhurst, Noam Levin, Sivasish Sindiri, Abraham Sachs, Kyle J. Hitscherich, Zhiya Yu, Nolan R. Vale, Yong-Chen Lu, Zhili Zheng, Li Jia, Jared J. Gartner, Victoria K. Hill, Amy R. Copeland, Shirley K. Nah, Robert V. Masi, Billel Gasmi, Scott Kivitz, Biman C. Paria, Maria Florentin, Sanghyun P. Kim, Ken-ichi Hanada, Yong F. Li, Lien T. Ngo, Satyajit Ray, Mackenzie L. Shindorf, Shoshana T. Levi, Ryan Shepherd, Chris Toy, Anup Y. Parikh, Todd D. Prickett, Michael C. Kelly, Rachel Beyer, Stephanie L. Goff, James C. Yang, Paul F. Robbins, Steven A. Rosenberg
Publikováno v:
Science
The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge for the engineering of cell-based cancer immunotherapies. By mapping 55 neoantigen-specific TCR clonotypes (NeoTCRs) from 10 metastatic human tumors to thei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1ba579b358ec71ec1fa0282916ff406
https://pubmed.ncbi.nlm.nih.gov/35113651
https://pubmed.ncbi.nlm.nih.gov/35113651
Autor:
Noam Levin, Frank J. Lowery, Maria R. Parkhurst, Zhiya Yu, Nolan R. Vale, Sanghyun P. Kim, Steven A. Rosenberg
Publikováno v:
Cancer Research. 82:3576-3576
Immunotherapies mediate the regression of human tumors through the recognition of tumor antigens by immune cells, which triggers an immune response. Mutations in the RAS oncogene occur across various cancer histologies and are found in about 30% of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4b4f84d31b307f630fc736adccd59e1
https://doi.org/10.1158/1538-7445.am2022-3576
https://doi.org/10.1158/1538-7445.am2022-3576
Autor:
Noam, Levin, Biman C, Paria, Nolan R, Vale, Rami, Yossef, Frank J, Lowery, Maria R, Parkhurst, Zhiya, Yu, Maria, Florentin, Gal, Cafri, Jared J, Gartner, Mackenzie L, Shindorf, Lien T, Ngo, Satyajit, Ray, Sanghyun P, Kim, Amy R, Copeland, Paul F, Robbins, Steven A, Rosenberg
Publikováno v:
Clin Cancer Res
BACKGROUND: Immunotherapies mediate the regression of human tumors through recognition of tumor antigens by immune cells that trigger an immune response. Mutations in the RAS oncogenes occur in about 30% of all cancer patients. These mutations play a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1c8b4d4424151bde93050f210271c479
https://pubmed.ncbi.nlm.nih.gov/34168045
https://pubmed.ncbi.nlm.nih.gov/34168045